Filtered By:
Condition: Thrombocytopenia
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 366 results found since Jan 2013.
Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
CONCLUSION: This study shows acceptable safety profiles of COVID-19 vaccines among recipients of BNT162b2, CoronaVac, and ChAdOx1 vaccines. This information can be used together with effectiveness data for risk-benefit analysis of the vaccination program. Further surveillance with more data is required to assess AESIs following COVID-19 vaccination in short- and long-term.PMID:35667917 | PMC:PMC9163997 | DOI:10.1016/j.vaccine.2022.05.075
Source: Vaccine - June 6, 2022 Category: Allergy & Immunology Authors: Norazida Ab Rahman Ming Tsuey Lim Fei Yee Lee Sing Chet Lee Azuana Ramli Siti Nurhafizah Saharudin Teck Long King Emelyne Bani Anak Jam Nor Aliya Ayub Raj Kumar Sevalingam Rashidah Bahari Nor Nadziroh Ibrahim Fatihah Mahmud Sheamini Sivasampu Kalaiarasu M Source Type: research
Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic Thrombocytopenia
In conclusion, insufficient resolution of NETs, e.g. by endogenous DNases or protection of NETs against degradation by embedded factors like the antimicrobial peptide LL-37 might thus be an important factor in the pathology of VITT besides increased NET-formation. On the basis of these findings, we discuss the potential implications of the mechanisms of disturbed NETs-degradation for diagnostic and therapeutic approaches in VITT-related thrombogenesis, other auto-immune disorders and beyond.
Source: Frontiers in Immunology - May 10, 2022 Category: Allergy & Immunology Source Type: research
Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia following COVID-19 Vaccine: A Case Report with Systematic Review of the Literature
Conclusion: Our study points out that, in addition to cerebral venous thrombosis, adenoviral vector-based vaccines also appear to have a cerebral arterial thrombotic risk, and clinicians should be aware that ischemic stroke with LVO, although rare, could represent a clinical presentation of VITT.Cerebrovasc Dis
Source: Cerebrovascular Diseases - May 5, 2022 Category: Neurology Source Type: research
Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic
CONCLUSION: Rates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.PMID:35465977 | DOI:10.1016/j.vaccine.2022.04.037
Source: Vaccine - April 25, 2022 Category: Allergy & Immunology Authors: Stanley Xu Vennis Hong Lina S Sy Sungching C Glenn Denison S Ryan Kerresa L Morrissette Jennifer C Nelson Simon J Hambidge Bradley Crane Ousseny Zerbo Malini B DeSilva Jason M Glanz James G Donahue Elizabeth Liles Jonathan Duffy Lei Qian Source Type: research
Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination
Circ Res. 2022 Apr 15;130(8):1187-1203. doi: 10.1161/CIRCRESAHA.122.319954. Epub 2022 Apr 14.ABSTRACTThe risk of stroke and cerebrovascular disease complicating infection with SARS-CoV-2 has been extensively reported since the onset of the pandemic. The striking efforts of many scientists in cooperation with regulators and governments worldwide have rapidly brought the development of a large landscape of vaccines against SARS-CoV-2. The novel DNA and mRNA vaccines have offered great flexibility in terms of antigen production and led to an unprecedented rapidity in effective and safe vaccine production. However, as mass vac...
Source: Circulation Research - April 14, 2022 Category: Cardiology Authors: Manuela De Michele Joshua Kahan Irene Berto Oscar G Schiavo Marta Iacobucci Danilo Toni Alexander E Merkler Source Type: research
Cerebral venous sinus thrombosis : An overview of causes, diagnostics and treatment
This article presents the most common causes, including a digression on vaccine-induced immune thrombotic thrombocytopenia (VITT) as well as recommendations for clinical, laboratory testing and imaging diagnostics. In addition, relevant complications with particular reference to epileptic seizures within the framework of the disease entity and guideline-based acute treatment and secondary prophylaxis are presented.PMID:35412038 | PMC:PMC9004207 | DOI:10.1007/s00115-022-01283-5
Source: Der Nervenarzt - April 12, 2022 Category: Neurology Authors: Jan Heckelmann Manuel Dafotakis J örg B Schulz Source Type: research
Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia
Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, which is associated with an increased risk of thromboembolism, heart failure and mortality.1 Previous studies in atrial fibrillation patients have reported that abnormal hemoglobin and platelet counts may be associated with adverse events. However, these studies that specifically examined the associations between hemoglobin and platelet levels and adverse outcomes reported conflicting data.2-5 Although warfarin effectively reduces the risk of ischemic stroke by 64% compared to placebo/control,6 and non-vitamin K antagonist oral antico...
Source: The American Journal of Medicine - April 2, 2022 Category: General Medicine Authors: Yung-Hsin Yeh, Yi-Hsin Chan, Shao-Wei Chen, Shang-Hung Chang, Chun-Li Wang, Chi-Tai Kuo, Gregory Y.H. Li, Shih-Ann Chen, Tze-Fan Chao Tags: Clinical Research Study Source Type: research
Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019
CONCLUSIONS: Our findings provide recent and comprehensive data on the epidemiology of CVST and CVST with thrombocytopenia.PMID:35284775 | PMC:PMC8901465 | DOI:10.1002/rth2.12682
Source: Thrombosis and Haemostasis - March 14, 2022 Category: Hematology Authors: Amanda B Payne Alys Adamski Karon Abe Nimia L Reyes Lisa C Richardson William Craig Hooper Laura A Schieve Source Type: research
Anticoagulants for people hospitalised with COVID-19
CONCLUSIONS: When compared to a lower-dose regimen, higher-dose anticoagulants result in little to no difference in all-cause mortality and increase minor bleeding in people hospitalised with COVID-19 up to 30 days. Higher-dose anticoagulants possibly reduce pulmonary embolism, slightly increase major bleeding, may result in little to no difference in hospitalisation time, and may result in little to no difference in deep vein thrombosis, stroke, major adverse limb events, myocardial infarction, atrial fibrillation, or thrombocytopenia. Compared with no treatment, anticoagulants may reduce all-cause mortality but the evide...
Source: Cochrane Database of Systematic Reviews - March 4, 2022 Category: General Medicine Authors: Ronald Lg Flumignan Vinicius T Civile J éssica Dantas de Sá Tinôco Patricia If Pascoal Libnah L Areias Charbel F Matar Britta Tendal Virginia Fm Trevisani Álvaro N Atallah Luis Cu Nakano Source Type: research
